Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study

伊库利珠单抗 非典型溶血尿毒综合征 医学 内科学 队列 人口 危险系数 肾功能 胃肠病学 置信区间 免疫学 补体系统 抗体 环境卫生
作者
Vicky Brocklebank,Patrick R. Walsh,Kate Smith‐Jackson,Thomas M Hallam,Kevin J. Marchbank,Valerie Wilson,Theophile Bigirumurame,Tina Dutt,Emma Montgomery,Michal Malina,Edwin KS Wong,Sally Ann Johnson,Neil Sheerin,David Kavanagh
出处
期刊:Blood [Elsevier BV]
卷期号:142 (16): 1371-1386 被引量:88
标识
DOI:10.1182/blood.2022018833
摘要

Historically, the majority of patients with complement-mediated atypical hemolytic uremic syndrome (CaHUS) progress to end-stage kidney disease (ESKD). Single-arm trials of eculizumab with a short follow-up suggested efficacy. We prove, for the first time to our knowledge, in a genotype matched CaHUS cohort that the 5-year cumulative estimate of ESKD-free survival improved from 39.5% in a control cohort to 85.5% in the eculizumab-treated cohort (hazard ratio, 4.95; 95% confidence interval [CI], 2.75-8.90; P = .000; number needed to treat, 2.17 [95% CI, 1.81-2.73]). The outcome of eculizumab treatment is associated with the underlying genotype. Lower serum creatinine, lower platelet count, lower blood pressure, and younger age at presentation as well as shorter time between presentation and the first dose of eculizumab were associated with estimated glomerular filtration rate >60 ml/min at 6 months in multivariate analysis. The rate of meningococcal infection in the treated cohort was 550 times greater than the background rate in the general population. The relapse rate upon eculizumab withdrawal was 1 per 9.5 person years for patients with a pathogenic mutation and 1 per 10.8 person years for those with a variant of uncertain significance. No relapses were recorded in 67.3 person years off eculizumab in those with no rare genetic variants. Eculizumab was restarted in 6 individuals with functioning kidneys in whom it had been stopped, with no individual progressing to ESKD. We demonstrated that biallelic pathogenic mutations in RNA-processing genes, including EXOSC3, encoding an essential part of the RNA exosome, cause eculizumab nonresponsive aHUS. Recessive HSD11B2 mutations causing apparent mineralocorticoid excess may also present with thrombotic microangiopathy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
流苏发布了新的文献求助10
1秒前
搜集达人的应助被Yutong采纳,获得10
1秒前
2秒前
可可完成签到,获得积分10
2秒前
Erpan发布了新的文献求助10
2秒前
HaoruMeng完成签到,获得积分10
2秒前
打打的应助被zyy采纳,获得30
2秒前
hnu301发布了新的文献求助10
3秒前
eason楽完成签到,获得积分20
3秒前
3秒前
醋酸柠檬完成签到,获得积分10
4秒前
朴素小鸟胃完成签到,获得积分10
4秒前
5秒前
菠菜的应助被cloud云采纳,获得10
5秒前
6秒前
6秒前
mmyhn发布了新的文献求助10
6秒前
秋风的应助被Liu采纳,获得10
6秒前
今后的应助被yy采纳,获得10
7秒前
7秒前
7秒前
hnu301完成签到,获得积分10
8秒前
君呱子完成签到 ,获得积分10
8秒前
可爱的函函的应助被lee采纳,获得10
9秒前
疯狂的海白完成签到,获得积分10
9秒前
安静翎发布了新的文献求助10
9秒前
10秒前
dgdsnfds发布了新的文献求助10
10秒前
何浏亮发布了新的文献求助10
10秒前
chipmunk完成签到,获得积分10
11秒前
11秒前
leslieyw完成签到,获得积分10
12秒前
酷波er的应助被六百六十六采纳,获得10
12秒前
qqq发布了新的文献求助10
12秒前
14秒前
linzx009完成签到,获得积分10
15秒前
16秒前
Xin完成签到,获得积分10
17秒前
Tang发布了新的文献求助10
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181940
求助须知:如何正确求助?哪些是违规求助? 9571697
关于积分的说明 21819181
捐赠科研通 7778330
什么是DOI,文献DOI怎么找? 3433556
关于科研通互助平台的介绍 2557767
邀请新用户注册赠送积分活动 2479621